FIGURE 8.

Schematic representation of the roles of SRXN1 in HCC tumorigenesis and metastasis. A, The SRXN1/p65/BTG2 signalling axis modulates cell growth and metastasis in vitro. SRXN1 constrains cellular ROS levels, which results in the degradation of I‐κb and the activation of p65. The accumulation of p65 in the nucleus suppresses the expression of BTG2 and ultimately promotes HCC cell growth and EMT. B, In vivo analysis of the role of SRXN1 in mouse models. Tumour growth was monitored in a subcutaneous xenograft model established with control or SRXN1‐silenced cells. Meanwhile, Hep3B cells were injected into mice via the tail vein. Metastatic nodules in the lungs of the mice were monitored and counted to analyse the pro‐metastatic role of SRXN1